Errata: Safety and efficacy of plerixafor dose escalation for the mobilization of CD34 + hematopoietic progenitor cells in patients with sickle cell disease: Interim results(Haematologica (2018) 103, 5 (770-777) 10.3324/haematol.2017.187047);Safety and efficacy of plerixafor dose escalation for the mobilization of cd34 + hematopoietic progenitor cells in patients with sickle cell disease: Interim results

Haematologica

Volumn 103, Issue 5, 2018, Pages 770-777

  Boulad, Farid ^a   Shore, Tsiporah ^b   van Besien, Koen ^b   Minniti, Caterina ^c   Barbu Stevanovic, Mihaela ^d   Fedus, Sylvie Wiener ^a   Perna, Fabiana ^a   Greenberg, June ^b   Guarneri, Danielle ^b   Nandi, Vijay ^d   Mauguen, Audrey ^a   Yazdanbakhsh, Karina ^d   Sadelain, Michel ^a   Shi, Patricia A ^c,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD18 ANTIGEN; CD34 ANTIGEN; DEFERASIROX; HYDROXYUREA; L SELECTIN; PLERIXAFOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTISICKLING AGENT; HETEROCYCLIC COMPOUND; PLERIXAFOR OCTAHYDROCHLORIDE;

ADULT; ARTICLE; AVASCULAR NECROSIS; CLINICAL ARTICLE; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; LEG ULCER; LEUKAPHERESIS; MALE; MONOCYTE; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PRIAPISM; RETINA ARTERY OCCLUSION; RETINOPATHY; SICKLE CELL ANEMIA; STEM CELL MOBILIZATION; YOUNG ADULT; CELL CULTURE; CYTOLOGY; DRUG EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ANEMIA, SICKLE CELL; ANTI-HIV AGENTS; ANTIGENS, CD34; ANTISICKLING AGENTS; CELLS, CULTURED; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 85046348539     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2018.199414     Document Type: Erratum

References (49)

1. Mansilla-Soto J, Riviere I, Sadelain M. Genetic strategies for the treatment of sickle cell anaemia. Br J Haematol. 2011;154(6): 715-727.
2. Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376 (9):848-855.
3. Sadelain M, Boulad F, Lisowki L, Moi P, Riviere I. Stem cell engineering for the treatment of severe hemoglobinopathies. Curr Mol Med. 2008;8(7):690-697.
4. Tisdale JF, Pierciey Jr. JF, Kanter J, et al. Successful Plerixafor-mediated mobilization, apheresis, and lentiviral vector transduction of hematopoietic stem cells in patients with severe sickle cell disease. Blood. 2017;130 (Suppl 1):990.
5. Fitzhugh CD, Hsieh MM, Bolan CD, Saenz C, Tisdale JF. Granulocyte colony-stimulating factor (G-CSF) administration in individ uals with sickle cell disease: time for a moratorium? Cytotherapy. 2009;11(4):464-471.
6. Petit I, Szyper-Kravitz M, Nagler A, et al. G- CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002;3(7): 687-694.
7. Cella G, Marchetti M, Vignoli A, et al. Blood oxidative status and selectins plasma levels in healthy donors receiving granulocytecolony stimulating factor. Leukemia. 2006;20(8):1430-1434.
8. de Haas M, Kerst JM, van der Schoot CE, et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood. 1994;84(11): 3885-3894.
9. Falanga A, Marchetti M, Evangelista V, et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood. 1999;93(8):2506-2514.
10. Spiel AO, Bartko J, Schwameis M, et al. Increased platelet aggregation and in vivo platelet activation after granulocyte colony-stimulating factor administration. A randomised controlled trial. Thromb Haemost. 2011;105(4):655-662.
11. Canales MA, Arrieta R, Gomez-Rioja R, Diez J, Jimenez-Yuste V, Hernandez-Navarro F. Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors. J Hematother Stem Cell Res. 2002;11(4):675-681.
12. Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127(7):801-809.
13. Schroeder MA, Rettig MP, Lopez S, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood. 2017;129 (19):2680-2692.
14. Choi E, Branch C, Cui MH, et al. No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice. Blood Cells Mol Dis. 2016;57:67-70.
15. Charache S. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin Hematol. 1997;34(3 Suppl 3):15-21.
16. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood. 1994;84(2):643-649.
17. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645-1651.
18. Litos M, Sarris I, Bewley S, Seed P, Okpala I, Oteng-Ntim E. White blood cell count as a predictor of the severity of sickle cell disease during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2007;133(2):169-172.
19. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644.
20. Pantin J, Purev E, Tian X, et al. Effect of high-dose plerixafor on CD34(+) cell mobilization in healthy stem cell donors: results of a randomized crossover trial. Haematologica. 2017;102(3):600-609.
21. Lamming CE, Augustin L, Blackstad M, Lund TC, Hebbel RP, Verfaillie CM. Spontaneous circulation of myeloid-lym-phoid-initiating cells and SCID-repopulating cells in sickle cell crisis. J Clin Invest. 2003;111(6):811-819.
22. Croizat H, Ponchio L, Nicolini FE, Nagel RL, Eaves CJ. Primitive haematopoietic progenitors in the blood of patients with sickle cell disease appear to be endogenously mobilized. Br J Haematol. 2000;111 (2):491-497.
23. Yannaki E, Papayannopoulou T, Jonlin E, et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe beta-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther. 2012;20(1):230-238.
24. Richard RE, Siritanaratkul N, Jonlin E, Skarpidi E, Heimfeld S, Blau CA. Collection of blood stem cells from patients with sickle cell anemia. Blood Cells Mol Dis. 2005;35(3):384-388.
25. Manwani D, Chen G, Carullo V, et al. Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis. Am J Hematol. 2015;90(5):381-385.
26. Jakubowski JA, Zhou C, Jurcevic S, et al. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thromb Res. 2014;133(2):190-195.
27. Canalli AA, Proenca RF, Franco-Penteado CF, et al. Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin. Haematologica. 2011;96(4):526-533.
28. Wun T, Styles L, DeCastro L, et al. Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia. PLoS One. 2014;9(7):e101301.
29. Nur E, van Beers EJ, Martina S, et al. Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis. Blood Cells Mol Dis. 2011;46(3):189-194.
30. de la Rubia J, Lorenzo JI, Torrabadella M, Marin P, Insunza A, Sanz MA. Basal CD34(+) cell count predicts peripheral blood progenitor cell mobilization and collection in healthy donors after administration of granulocyte colony-stimulating factor. Haematologica. 2004;89(12):1530-1532.
31. Martino M, Gori M, Pitino A, et al. Basal CD34(+) Cell count predicts peripheral blood stem cell mobilization in healthy donors after administration of granulocyte colony-stimulating factor: a longitudinal, prospective, observational, single-center, cohort study. Biol Blood Marrow Transplant. 2017;23(7):1215-1220.
32. Kanter J, Walters MC, Hsieh MM, et al. Interim results from a phase 1/2 clinical study of lentiglobin gene therapy for severe sickle cell disease. Blood. 2017;128 (22):1176.
33. Uchida N, Fujita A, Hsieh MM, et al. Bone marrow as a hematopoietic stem cell source for gene therapy in sickle cell disease: evidence from Rhesus and SCD patients. Hum Gene Ther Clin Dev. 2017;28(3):136-144.
34. Miller ST, Rey K, He J, et al. Massive acci dental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatr Blood Cancer. 2012;59(1):170-172.
35. Castro O, Nouraie M, Oneal P. Hydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefit. Br J Haematol. 2014;167(5):687-691.
36. Brunson A, Keegan THM, Bang H, Mahajan A, Paulukonis S, Wun T. Increased risk of leukemia among sickle cell disease patients in California. Blood. 2017;130(13):1597-1599.
37. Drasar ER, Jiang J, Gardner K, et al. Leucocyte telomere length in patients with sickle cell disease. Br J Haematol. 2014;165 (5):725-727.
38. Baird JH, Minniti CP, Lee JM, et al. Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide. Br J Haematol. 2015;168(5):737-746.
39. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039-2045.
40. Worel N, Frank N, Frech C, Fritsch G. Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes. Transfusion. 2017;57(9): 2206-2215.
41. Javazon EH, Radhi M, Gangadharan B, Perry J, Archer DR. Hematopoietic stem cell function in a murine model of sickle cell disease. Anemia. 2012;2012:387385.
42. Leonard A, Bonifacino A, Dominical VM, et al. Bone marrow characterization in sickle cell disease: inflammation and stress erythropoiesis lead to suboptimal CD34 recovery compared to normal volunteer bone marrow. Blood. 2017;130(Suppl 1):966.
43. Dallalio G, Brunson CY, Means RT, Jr. Cytokine concentrations in bone marrow of stable sickle cell anemia patients. J Investig Med. 2007;55(2):69-74.
44. Colella MP, Santana BA, Conran N, et al. Telomere length correlates with disease severity and inflammation in sickle cell disease. Rev Bras Hematol Hemoter. 2017;39 (2):140-145.
45. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102(8): 2728-2730.
46. Eidenschink L, DiZerega G, Rodgers K, Bartlett M, Wells DA, Loken MR. Basal levels of CD34 positive cells in peripheral blood differ between individuals and are stable for 18 months. Cytometry B Clin Cytom. 2012;82(1):18-25.
47. Hoggatt J, Singh P, Tate TA, et al. Rapid mobilization reveals a highly engraftable hematopoietic stem cell. Cell. 2018;172(1-2):191-204.e10.
48. Lemery SJ, Hsieh MM, Smith A, et al. A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers. Br J Haematol. 2011;153(1):66-75.
49. Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of single human hematopoietic stem cells capable of longterm multilineage engraftment. Science. 2011;333(6039):218-221.